Analyst Price Targets — AXSM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 2:04 pm | — | RBC Capital | $222.00 | $168.35 | TheFly | Axsome Therapeutics price target raised to $222 from $219 at RBC Capital |
| February 24, 2026 12:56 pm | — | UBS | $251.00 | $170.81 | TheFly | Axsome Therapeutics price target raised to $251 from $248 at UBS |
| February 24, 2026 12:37 pm | — | Morgan Stanley | $207.00 | $174.76 | TheFly | Axsome Therapeutics price target raised to $207 from $204 at Morgan Stanley |
| February 24, 2026 11:35 am | — | Guggenheim | $220.00 | $174.76 | TheFly | Axsome Therapeutics price target raised to $220 from $205 at Guggenheim |
| February 24, 2026 11:11 am | — | Wells Fargo | $202.00 | $174.76 | TheFly | Axsome Therapeutics price target raised to $202 from $193 at Wells Fargo |
| February 23, 2026 9:10 pm | Rudy Li | Wolfe Research | $230.00 | $174.76 | TheFly | Axsome Therapeutics initiated with an Outperform at Wolfe Research |
| February 23, 2026 5:32 pm | Joon Lee | Truist Financial | $200.00 | $173.55 | StreetInsider | Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM) |
| February 23, 2026 5:17 pm | — | Jefferies | $215.00 | $173.90 | StreetInsider | Axsome Therapeutics (AXSM) PT Raised to $215 at TD Cowen |
| February 19, 2026 12:18 pm | — | Mizuho Securities | $230.00 | $184.74 | TheFly | Axsome Therapeutics price target raised to $230 from $217 at Mizuho |
| January 21, 2026 11:33 am | Leonid Timashev | RBC Capital | $219.00 | $184.50 | TheFly | Axsome Therapeutics price target raised to $219 from $212 at RBC Capital |
Latest News for AXSM
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in March:
Axsome misses Q4 estimates for earnings. Revenues jump 65% on strong Auvelity sales as well as other product sales and top estimates.
Axsome Therapeutics, Inc. delivered 66% full-year 2025 revenue growth to $638.5M, driven by Auvelity and Sunosi, but remains loss-making. Despite a robust pipeline and upcoming catalysts, I downgrade AXSM to Hold due to valuation risks and commercial uncertainties in competitive markets. AXSM's 2030 revenue could reach ~$3.5B in a best-case scenario, but achieving blockbuster status for key assets like Sunosi and…
The headline numbers for Axsome (AXSM) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.96 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AXSM.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.